Dr. Gadi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
818 S. Wolcott Ave
B404
Chicago, IL 60612Phone+1 312-996-1581
Summary
- Dr. V.K. Gadi is an oncologist based in Chicago, Illinois, with subspecialties in breast cancer and sarcoma. After receiving his medical degree from the University of Alabama Birmingham, he completed his residency at the University of Washington in Internal Medicine and fellowship in Medical Oncology at the Fred Hutchinson Cancer Center. He currently holds several roles including Deputy Director at the University of Illinois Cancer Center and Professor at the UIC Department of Medicine. Additionally, he has several publications in high impact journals, specifically focusing on breast cancer. Dr. Gadi is also actively involved in the design and implementation of clinical trials, often in the role of principal investigator.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2002 - 2006- University of WashingtonResidency, Internal Medicine, 2000 - 2002
University of Alabama School of MedicineClass of 2000
Certifications & Licensure
IL State Medical License 2020 - 2026
WA State Medical License 2002 - 2020
Clinical Trials
- Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery Start of enrollment: 2014 Jun 01
- BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer Start of enrollment: 2022 Jan 10
Roles: Contact, Principal Investigator
- Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI) Start of enrollment: 2023 Dec 28
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 15 citations18F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2- Metastatic Breast Cancer.Lanell M. Peterson, Brenda F. Kurland, Fengting Yan, Alena Novakova Jiresova, Vijayakrishna K. Gadi
Journal of Nuclear Medicine. 2021-02-01 - 74 citationsAdjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical TrialSara M. Tolaney, Nabihah Tayob, Chau T. Dang, Denise A. Yardley, Steven J. Isakoff
Journal of Clinical Oncology. 2021-06-02 - 2 citationsAdjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Corre...Paolo Tarantino, Nabihah Tayob, Guillermo Villacampa, Chau Dang, Denise A Yardley
Journal of Clinical Oncology. 2024-11-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
